ciraparantag

Ciraparantag is a synthetic, small, water-soluble molecule under investigation as a universal anticoagulant reversal agent. It is designed to rapidly reverse the effects of various anticoagulants, including direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran, as well as low-molecular-weight heparins (LMWH) and unfractionated heparin. Ciraparantag acts by binding noncovalently—through hydrogen bonds and charge-charge interactions—to these anticoagulant drugs. This binding prevents the drugs from interacting with their biological targets (such as factor Xa or thrombin), thereby reversing their anticoagulant effects and restoring normal clotting function. The drug has demonstrated rapid onset of action in clinical studies and is being developed for use in situations requiring urgent reversal of anticoagulation due to life-threatening bleeding or emergency surgery[1][2][4][5][6][7].

Other names

aripazineciraparantagum